"Aimovig provides patients with a novel option for reducing the number of days with migraine," said Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "We need new treatments for this painful and often debilitating condition."

Patients often describe migraine headache pain as an intense pulsing or throbbing pain in one area of the head. Additional symptoms include nausea and/or vomiting and sensitivity to light and sound. Approximately one-third of affected individuals can predict the onset of a migraine because it is preceded by an aura—transient sensory or visual disturbances that appear as flashing lights, zig-zag lines or a temporary loss of vision. People with migraine tend to have recurring attacks triggered by a number of different factors, including stress, hormonal changes, bright or flashing lights, lack of food or sleep and diet. Migraine is three times more common in women than in men and affects more than 10 percent of people worldwide.

The effectiveness of Aimovig for the preventive treatment of migraine was evaluated in three clinical trials. The first study included 955 participants with a history of episodic migraine and compared Aimovig to placebo. Over the course of six months, Aimovig-treated patients experienced, on average, one to two fewer monthly migraine days than those on placebo. The second study included 577 patients with a history of episodic migraine and compared Aimovig to placeb.
Over the course of three months, Aimovig-treated patients experienced, on average, one fewer migraine day per month than those on placebo. The third study evaluated 667 patients with a history of chronic migraine and compared Aimovig to placebo. In that study, over the course of three months, patients treated with Aimovig experienced, on average, 2 ½ fewer monthly migraine days than those receiving placebo.

The most common side effects that patients in the clinical trials reported were injection site reactions and constipation.

The FDA granted the approval of Aimovig to Amgen Inc.

To receive daily emails from Breaking Christian News to your inbox CLICK HERE

An Easter Miracle!! 2nd Crew Member from Downed Jet in Iran Rescued and Safely Extracted after Intense Race to Reach Him before IRGC Terrorists

PRAYER ALERT: US F-15 Fighter Jet Downed in SW Iran, 1 Pilot Rescued and Safe; Search Continues for Second One

Dutch Sheets: Good Friday Message & Communion

'I Began to Pray': Pastor Talks Down Crazed Man Who Points Gun Directly at Him, Leads 10 to Christ

Trump HHS Renews Planned Parenthood Grants for 'Final Year' Due to Legalities, But 'Funds CANNOT Be Used for Abortions'

WATCH: Families at the Center of Washington State Transgender Sports Debate Stand Firm for Truth

Levin: Ruling Against Birthright Citizenship Should Be a 'Slam-Dunk' for Supreme Court [Video]

Colorado Appeals Court Reverses Tina Peters' Sentencing, Could This Lead to Her Freedom?

March Job Growth Triples Expectations, Unemployment Rate Dips

Artemis II Mission Pilot: 'We Need Jesus; Whether Here on Earth or Orbiting the Moon'

Democrat Lawmaker Steps Down, Says Faith No Longer Aligns with Left's Agenda

Trump Administration Charges 9 in Massive Massachusetts Fraud Scheme

ICE Finally Detains Notorious Hamas Fundraiser Salah Sarsour; Decades of Terror Ties Exposed as AMP Leader Faces Deportation

Johnson, Thune Hatch Plan to Fund DHS and Launch a Second Reconciliation Push to End the Dem's Shutdown

Pentagon Briefed Trump on Plan to Seize Uranium from Hands of Iranian Terrorist Regime

President Trump Reassures Americans: Iran Operation Won't Be a Forever War

Pam Bondi OUT as Attorney General

Countdown for Historic Space Mission Artemis II Begins

Federal Judge Orders Trump Administration to Halt Construction on Privately Funded White House Ballroom; Trump Responds

Trump Rolls Out a Plan to Back Farmers amid Rising Costs, Pledging 'Golden Age'